Skip to content
Screener

NovoCure NVCR Q2 2026 earnings

Reported July 23, 2026 · Before market open

Revenue$183.6MBeat by $11.1M
EPS-$0.13Beat by $0.20
Revenue estimate$172.4M
EPS estimate-$0.33
“We continue to launch our therapies in multiple markets allowing us to bring TTFields therapy to many more patients who can benefit. We are well-positioned to advance our patient-forward mission while driving sustainable growth and making material progress on our path to profitability.”
Frank Leonard

Next report

Oct 29, 2026 (in a month)
Revenue estimate$182.3M
EPS estimate-$0.21

Financials

Q2 2026

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
Net income-$15.7M+61.0%
EPS (diluted)-$0.13+63.9%

Balance sheet

See full
Cash & equivalents$93.7M-37.4%
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
Operating cash flow$8.1M+151%
CapEx$6.9M+26.1%
Free cash flow$1.2M+106%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.89B+33.1%
Enterprise value$1.83B+39.7%
P/S2.7×+0.4×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Segments

By geography

See full
United States$103.0M—
Germany$23.3M—
France$21.3M—
Japan$11.8M—
Greater China$6.0M—

FAQ

When did NovoCure report Q2 2026 earnings?
NovoCure (NVCR) reported Q2 2026 earnings on July 23, 2026 before market open.
What were NovoCure's Q2 2026 revenue and EPS?
NovoCure reported revenue of $183.6M and eps of $-0.13 for Q2 2026.
Did NovoCure beat estimates in Q2 2026?
Revenue beat the consensus estimate of $172.4M by $11.1M. EPS beat the consensus estimate of $-0.33 by $0.20.
How did NovoCure's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 15.6% from $158.8M a year earlier and eps grew 63.9% from $-0.36.
Where can I find NovoCure's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001645113-26-000063) and the 10-Q periodic report (0001645113-26-000062) directly on SEC EDGAR. The filing index links above go to sec.gov.